AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Revolution Medicines, Inc.
Video analysis: RVMD
All videosNo video analysis for this stock yet. Request one from our team.
News: RVMD
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $3,585,823.80 in Stock
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) Director Lorence Kim sold 17,090 shares of the firm's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $209.82, for a total transaction of $3,585,823.80. The sale was disclosed in a filing with the SEC, which is accessible through
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year. Revolution Medicines is a clinical-stage oncology specialist focused on high-stakes breakthrough therapies for RAS-addicted cancers.
Revolution Medicines, Inc. $RVMD Shares Bought by Arizona State Retirement System
Arizona State Retirement System boosted its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 17.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 46,382 shares of the company's stock after buying an additional 6,986 shares during the quarter. Arizona State
Revolution Medicines Got Its Breakthrough—What Moves It Next?
Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC).
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions
Revolution Medicines maintains a strong buy rating following FDA approval of RASONQUE for 2nd-line metastatic PDAC, with significant expansion opportunities ahead. Company's pipeline includes zoldonrasib, targeting G12D-mutant PDAC and NSCLC, with two pivotal phase 3 trials underway in 1st-line settings, leveraging strong prior efficacy data. The company holds $3.9B in cash, supported by recent financings and a $2B Royalty Pharma agreement, providing at least 12 months of operational runway.
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan
Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer. RVMD's multi-selective approach addresses a broad spectrum of RAS mutations, positioning RASONQUE as a potential blockbuster with significant market opportunity. Despite a strong cash position ($3.9B), RVMD will incur substantial losses through 2028, with profitability only projected in 2029 as revenue ramps from global expansion.
